Abstract:Abstract Background Subjective cognitive decline (SCD) may provide an early indicator of evolving neurodegenerative disease. Dyadic SCD patterns, or understanding the self/patient’s in relation to an informant/loved one’s endorsement of SCD, may more accurately reflect underlying Alzheimer’s disease (AD) pathology in particular. We related dyadic discrepancies in SCD to markers of core AD pathology, including amyloid‐β 42 (Aβ 42 ) and phosphorylated tau (p‐tau). Method Vanderbilt Memory and Aging Project participants free of clinical dementia [n = 150, 72±7years, 37% mild cognitive impairment (MCI)] and their informants completed the Everyday Cognition questionnaire. Dyadic discrepancy (self‐reported score minus informant‐reported score) was calculated. Positive scores indicate self>informant SCD and negative scores indicate informant>self SCD. Participants also underwent fasting lumbar puncture to obtain cerebrospinal fluid (CSF) for quantification of Aβ 42 and p‐tau. Linear mixed‐effects regression models related dyadic score to individual CSF biomarkers adjusting for age, sex, self‐reported race/ethnicity, cognitive status, apolipoprotein E‐ ε4 status (positive, negative), and depression symptoms (Geriatric Depression Scale) with false discovery rate (FDR) corrections for multiple comparisons. Models were repeated with a diagnosis x biomarker interaction. Result SCD discrepancy in the negative direction (informant>self‐SCD) was associated with higher CSF p‐tau (β = ‐0.64, pFDRself‐SCD) had lower Aβ 42 levels (β = 5.592, pFDR = 0.02), indicating more cerebral amyloid deposition. The opposite pattern was observed in cognitively unimpaired participants, though findings did not survive FDR correction (β = 1.16, p = 0.03, pFDR = 0.24). Additionally, in MCI participants, negative SCD discrepancy was associated with higher p‐tau levels (β = ‐0.7223, pFDR = 0.02). All significant results survived outlier exclusion. See Figure for details. Conclusion Dyadic SCD discrepancy correlates with AD biomarkers differently in preclinical and prodromal states. In MCI, greater informant‐SCD related to more amyloid and p‐tau deposition, likely due to patient anosognosia and increasing functional changes noted by others. Conversely, in an earlier, preclinical stage before the onset of overt problems, more self‐SCD appears indicative of greater amyloid pathology. Results are consistent with the purported pathological cascade of AD and highlight the relevance of considering dyadic SCD to inform underlying disease.

Patterns of cognitive domain abnormalities enhance discrimination of dementia risk prediction: The ARIC study

Cognitive Performance and Incident Alzheimer's Dementia in Men Versus Women

Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging.

Comparison of subjective cognitive decline and polygenic risk score in the prediction of all-cause dementia, Alzheimer's disease and vascular dementia

Differential Cognitive Deterioration in Dementia: A Two Year Longitudinal Study

Incremental Value of Multidomain Risk Factors for Dementia Prediction: A Machine Learning Approach

Signatures of Neuropsychological Test Results in the Long Life Family Study: A Cluster Analysis

Executive Functioning and Processing Speed as Predictors of Global Cognitive Decline in Alzheimer Disease

Dyadic patterns of subjective cognitive decline relate to Alzheimer’s disease biomarkers differently in preclinical and prodromal clinical states

Risk factors and cognitive domain markers of progression in subjective cognitive decline

Predictors of Incident Mild Cognitive Impairment and Its Course in a Diverse Community-Based Population

Detecting Dementia: Novel Neuropsychological Markers of Preclinical Alzheimer&rsquo;s Disease

Performance on neuropsychological assessment and progression to dementia: A meta-analysis.

Cognitive reserve as residual variance in cognitive performance: Latent dimensionality, correlates, and dementia prediction

External validation of dementia prediction models in Black or African American and White older adults: A longitudinal population‐based study in the United States

Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease

Is an MRI-derived anatomical measure of dementia risk also a measure of brain aging?

Examining the Interactive Effect of Cardiovascular Risk Factors and APOE Genotype on Population Health Disparities in dementia risk

Patterns of Cognitive Decline, Conversion Rates, and Predictive Validity for 3 Models of MCI

Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer’s Disease

Patterns of structure-function association in normal aging and in Alzheimer's disease: Screening for mild cognitive impairment and dementia with ML regression and classification models